Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk

Abstract

This work was supported by NIH grant R01HL095964 to FMS and by a grant to the Harvard Clinical and Translational Science Center (8UL1TR0001750) from the National Center for Advancing Translational Science.

Associations of Perfluoroalkyl substances with blood lipids and Apolipoproteins in lipoprotein subspecies: the POUNDS-lost study

“…Current evidence suggests that blood lipid particles are highly heterogeneous and comprise a group of lipoproteins and apolipoproteins (such as apoC and apoE) with diverse biological functions [13,[15][16][17]. For instance, studies have shown that LDL that contains apoC-III, but not LDL that lacks apoC-III, was an independent risk factor for cardiovascular risk [18][19][20].…”

“…Two independent prospective studies showed that HDL cholesterol that contains or lacks apoC-III demonstrated opposite associations with the risk of coronary heart disease (CHD): HDL cholesterol that lacks apoC-III was inversely associated with CHD, whereas HDL cholesterol that contains apoC-III (small subfraction) was associated with a higher risk of CHD [16]. Further, the associations of apoE concentrations in HDL with cardiovascular risk significantly differ in the presence of apoC-III in that HDL with both apoE and apoC-III tended to be associated with a higher cardiometabolic risk [17,33,34]. Therefore, the heterogeneous lipoprotein subspecies deserve to be characterized in order to improve the disease risk prediction rather than relying on total lipid fractions [14].…”

“…Potential reasons for these inconsistent findings may involve differences in study designs and exposure levels, and another important concern is the metabolic and functional heterogeneity of lipoprotein subspecies [13,14]. Thus, what is commonly referred to as low-density lipoprotein (LDL), high-density lipoprotein (HDL), and other lipid fractions constitute diverse groups of lipoprotein particles with heterogeneous biological functions, varying in cholesterol and triglyceride contents, as well as attachments of apolipoprotein (apo) C and apoE [13,[15][16][17]. Accumulating evidence has suggested that apoC-III acts as an independent risk factor for cardiovascular disease [18][19][20].…”

“…Accumulating evidence has suggested that apoC-III acts as an independent risk factor for cardiovascular disease [18][19][20]. Further, the apoC-III attached to HDL could significantly attenuate the beneficial metabolic action of HDL apoE and subsequently affect lipid metabolism and cardiovascular disease risk [17]. So far, association between PFAS exposures and lipoprotein subspecies has apparently not been investigated.…”

Apolipoproteina E şi progresia nefropatiei la pacienţii diabetici

“…La pacienţii HiV pozitiv, homozigozitatea apo ε4 ne arată progresia spre SiDa şi creşterea susceptibilitităţii la infecţii oportuniste. apoe plasmatică apare în principal prin sinteză hepatică; la nivel cerebral, astrocitele produc o cantitate mare de lichid cefalorahidian ce conţine apoe (23,24,25). aSoCIEREa apoE cu unElE afEcţiuni apo ε4 aste asociată cu boala alzheimer familială cu debut tardiv.…”